cyrilzakka/clinical-trials huggingface dataset:
Physical Activity, Function and Quality of Life in Patients After Endovascular Treatment

The purpose of this study is to investigate how systematic physical training after endovascular treatment influence the durability of the endovascular treatment and how it effects physical function, quality of life and future cardiovascular events.


Eligibility Criteria:
Inclusion Criteria:

* 55 years old or older
* successful endovascular
* living in Oslo or in the close area being able to come to physical training classes at the hospital

Exclusion Criteria:

* endovascular treatment on study-leg last 2 years
* other reasons for reduced walking function than peripheral arterial disease
Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease

Active vitamin D at therapeutic dose may prevent vascular calcification but in supraphysiologic dose may precipitate it.

Active vitamin D compound is used frequently in the treatment of hyperparathyroidism in chronic kidney disease. Recent evidence from animal studies suggested that low dose of active vitamin D may be protective against vascular calcification, whereas high dose could precipitate it. The present study will examine the effect of low dose oral alfacalcidol on coronary artery calcification in predialysis chronic kidney disease patients with hyperparathyroidism.

Eligibility Criteria:
Inclusion Criteria:

* Predialysis chronic kidney disease with GFR \< 90 mL/min/1.73m2
* PTH above the upper limit of normal
* serum calcium and phosphate below the upper limit of normal

Exclusion Criteria:

* changes in GFR\>15% during the past 3 months
* receive elemental calcium\>500 mg/day
* currently taking active vitamin D, oral calcium with elemental calcium\>500 mg/day or bisphosphonate
Ear Plug and Eye Mask Use on Sleep Quality in Intensive Care Patients

This study was conducted as a pre-test and post-test randomized controlled single center study to evaluate the effect of ear plugs and eye mask application on sleep quality in patients hospitalized in the intensive care unit. 120 patients who received inpatient treatment in Siirt State Hospital general intensive care unit constitute the sample of the study. The sample consist of four groups: ear plug group (n=30), eye mask group (n=30), earplug-eye mask group (n=30) and control group (n=30). Data were collected using the "Patient Identification Form, Glasgow Coma Skale, Visual Analog Scale, Richards-Campbell Sleep Questionnaire (RCSQ), ear plug and eye mask". As a preliminary test, RCSQ was applied in the morning of the second day after the first night sleep of the patients. Then, according to the group they were assigned to, the patients were allowed to sleep by applying only ear plug, eye mask only and simultaneous ear plug-eye mask between 22:00-06:00. As a final test, RCSQ was readministered to patients on the morning of the third day after the second night's sleep. During the analysis of the data, frequency, number, mean, Student t test and/or Mann- Whitney U test, ANOVA and/or Kruskal- Wallis test, t test or Wilcoxon Sign test, chi-square test were used.


Eligibility Criteria:
Inclusion Criteria:

Being 18 years or older

* Being literate
* No hearing impairment
* Ability to communicate verbally
* Receiving inpatient treatment in the GICU for at least 3 days
* Have 15 Glasgow Coma Scale (GCS) scores (Minimum scores will be as follows. 3 points from eye response; 5 points from motor response; 2 points from verbal response)
* Agreeing to participate in the research

Exclusion Criteria:

Having a Visual Analog Scale (VAS) score above 7

* Using sleeping pills or sedative drugs
* Being treated with a diagnosis of sleep disorder
* Being on mechanical ventilation
* Having an active ear or eye infection
* Having a diagnosed psychiatric illness
Effects of the Pressure and Traction Technique on the Plantar Footprint and Balance

The aim of this clinical trial is to check the effects of manual pressure and traction technique on balance and plantar footprint variables comparing with Laser placebo.

Forty healthy subjects wil be recruited for a simple blind study. Participants will be from 1 to 40 years old, not obese. Participants will be randomized into two groups. Experimental group performed a bilateral plantar fascia manual pressure and traction technique. Control group performed a laser placebo. The time duration (5 minutes), position, and therapist were the same for both treatments. The investigators will measure stabilometry variables and static footprint. The footprint variables will be divided in bilateral rear foot, bilateral midfoot, bilateral fore foot.

Measures. Stabilometry will be measured by displacement of the center of pressures in X and Y with eyes open and closed , center of pressure (COP) with eyes open and closed, COP area with eyes open and closed, COP antero-posterior (a-p) and medio-lateral (m-lat) directions with eyes open and closed, and COP speed. Two trials will be recorded for each condition and the order of the conditions will be randomized across subjects, eyes open and eyes closed. Foot plantar pressure and surface area of two static footprints will be measured during bipedal standing. Static plantar pressure will be evaluated by means of maximum pressure, medium pressure and surface area of each aspect of the foot (rearfoot, midfoot, and fore foot).

Eligibility Criteria:
Inclusion Criteria:

* Healthy individuals
* Must have no pain

Exclusion Criteria:

* Previous lower extremities surgery.
* History of lower extremities injury with residual symptoms (pain, "giving-away" sensations) within the last year.
* Leg-length discrepancy more than 1 cm
* Balance deficits (determined by oral questionnaire regarding falls)
Effect of Celecoxib on Transitional Pain After Outpatient Surgery

Sixty adults having shoulder and forearm surgery will receive either placebo or celebrex started preoperatively and continued for 3 days. Rescue medications required as well as pain scores will be assessed using a patient diary to evaluate the effect of celebrex in controlling transitional pain


Eligibility Criteria:
Inclusion Criteria:

* Patients scheduled for elective ambulatory surgery of the shoulder
* ASA I - III
* Able to read English
* Male or female

Exclusion Criteria:

* Allergy to local anesthetic, Cox2, sulpha drug, acetaminophen or oxycodone
* Women who are pregnant or lactating and women of childbearing age and not following acceptable contraceptive precautions
* Any major medical or psychiatric problem
* Those with a known history of narcotic dependence, abuse or chronic narcotic intake
* Patients with known history of peptic ulcer or GI bleeding in the past, ulcers, congestive heart failure, angina or previous heart attack, coagulation problems, venous thrombosis, kidney or liver disease or strokes
Metformin in Intracytoplasmic Sperm Injection Cycles

The relationship between serum progesterone level on the day of human chorionic gonadotropin administration and outcome of in vitro fertilization /intracytoplasmic sperm injection and embryo transfer has been controversial for several decades. some studies presented data against the negative effect of premature luteinization and reported that elevated serum progesterone had no adverse effect on pregnancy rates in fresh embryo-transfer cycles within different ovarian responses. However, most studies have evaluated the association between serum progesterone level and clinical outcome in fresh in vitro fertilization /intracytoplasmic sperm injection cycles and advocated that serum progesterone elevation on the day of human chorionic gonadotropin administration may adversely affect the clinical outcome by jeopardizing endometrial receptivity.

In addition, the underlying mechanism through which premature luteinization influences clinical outcomes is elusive. some proposed that premature luteinization cause impairment of the endometrial receptivity, which may indicate a change in the implantation window, is more likely to be affected than the oocyte.whereas some documented that the compromised quality of oocytes might also be a cause.

The cut-off point of premature luteinization is not well established until now. Premature luteinization has been variously defined based on serum P levels, with thresholds of 0.9-1.5 ng/mL being used.

Previous studies have shown that metformin inhibits the first steps of steroidogenesis dose-dependently reducing granulosa cells progesterone output. Moreover, other authors have recently reported that low dose metformin could improve in vitro fertilization outcome in non poly-cystic ovarian syndrome repeaters. So, considering the safety of this drug before pregnancy, metformin can be given to consenting patients from first ultrasound monitoring until ovulation triggering.


Eligibility Criteria:
Inclusion Criteria:

* First or second trial ICSI cycle.
* Age: 20 -38 years
* BMI: patients with BMI ≥ 30 kg/m2 were advised to lose weight for 6 months through lifestyle modifications.
* AMH ≥1 ng/ml
* Basal FSH \< 10 IU/ml.
* Normal uterine cavity evidenced by HSG or office hysteroscopy
* Normal levels of prolactin and TSH before starting COS cycle

Exclusion Criteria:

* Patients with recurrent two or more failed intra-cytoplasmic sperm injection cycles.
* Uterine anomalies or Synechiae.
* Severe male factor infertility
* Patients known to have diabetes, renal, liver disease, alcoholism, or drug abuse were excluded
* Patients who were on metformin treatment were asked to have a one month washout period before study participation.
* Poor responders
Ascension® Humeral Resurfacing Arthroplasty (HRA) Follow-Up Study

This is a prospective study on the Ascension HRA device to collect data to assess the safety and effectiveness of the HRA.

This study protocol will provide guidance to investigators wanting to perform a non-randomized, consecutive enrollment, 10-year follow-up study of patients who are treated with the Ascension® HRA. Its purpose is to measure and document the outcomes associated with implanting the Ascension HRA prosthesis. Patients will be periodically assessed to collect data related to safety and effectiveness endpoints at the following intervals: preoperative, surgery/immediate post-op, 3 months, 6 months, 1 year, 2 year, 5 year, and 10 years.

Eligibility Criteria:
Inclusion Criteria:

Any patient who is to be treated with the Ascension HRA is eligible for inclusion in this study. Therefore, Principal Investigators should attempt to recruit all patients at the study site who are treated with the Ascension HRA

The following patient will be included in the study - Patient who:

* Is treated with the Ascension HRA
* Is disabled by either non-inflammatory or inflammatory arthritis (i.e. rheumatoid arthritis, osteoarthritis and avascular necrosis
* Has mild or moderate humeral head deformity and /or limited motion
* Has post-traumatic arthritis
* Has an intact or reparable rotator cuff
* Has the means and ability to return for all required study visits
* Is willing to participate in the study
* Has signed an Informed Consent Form
* Is at least 18 years of age and skeletally mature at the time of surgery
* Is less than 75 years of age at the time of surgery

Exclusion Criteria:

* Infection, sepsis, and osteomyelitis
* Osteoporosis
* Metabolic disorders which may impair bone formation
* Osteomalacia
* Rapid joint destruction, marked bone loss or bone resorption apparent on X-ray
* Revision procedures where other devices or treatments have failed
* Refuses to be in the study; or does not have the means and ability to return for all required study visits
* Currently participating in another clinical study
The Effects of Sleep Variability in Youth

Daily sleep variability is prevalent in the young populations, yet its effects remain less clear. The experimental study aims to examine the impacts of intraindividual daily sleep variability on sleep characteristics, cardiometabolic regulations and daytime functioning in college students.


Eligibility Criteria:
Inclusion Criteria:

* Habitual sleep duration \> 7 h/day.

Exclusion Criteria:

* Extreme morning- nor extreme evening-chronotype
* With sleep problems
* With mood and anxiety problems
* With excessive daytime sleepiness
* Have history of any chronic medical condition and on regular medication.
Use of the Epidermal Micrografts for Wound Healing After Mohs or Excisional Surgery for Skin Cancer

This case series will assess the use of suction blister epidermal grafts harvested by a novel device on select patients that have wounds from Mohs or excisional surgery.

This study evaluates a novel micrografting technique to determine how it will influence the healing and cosmetic result of selected post surgical wounds in 12 subjects. The Epidermal Expansion System (designed by MoMelan Technologies) will generate an array of small microblisters and transfer the micrografts to a sterile wound dressing for application to the subject's surgical area. The sponsor hypothesizes that applying expanded micrografts to wounds that otherwise would have healed by second intention alone will hasten healing and possibly reduce scarring.

Eligibility Criteria:
Inclusion Criteria:

* Adult males and females between 35 and 90 years of age
* Status post skin cancer removal on the scalp, ear or leg with a wound that would otherwise be allowed to heal by secondary intention or grafting
* Wound considered appropriate by physician to receive epidermal grafting
* Willingness to participate in study by evidence of informed consent

Exclusion Criteria:

* Female patients reported to be breastfeeding, pregnant or planning to become pregnant
* Clinical signs of infection
* Subjects currently on immunosuppressive medications, chemotherapy or a cytotoxic agent
* Participation in another interventional study with potential exposure to an investigational drug or device within the past 30 days or planned study entry within 90 days after study entrance.
Median Effective Dose of Lidocaine for the Prevention of Pain Caused by the Injection of Propofol Formulated With Medium-/Long-chain Triglycerides

Propofol is widely used in general anesthesia induction, but the occurrence of peripheral intravenous pain is relatively high, causing anxiety, fear and other adverse emotions in patients , aggravating the stress response, and even leading to adverse events of cardiovascular system . The use of mediate-long chain fat emulsion propofol partly reduces the incidence of injection pain but patients can still suffer from different degrees of pain. Advanced intravenous injection of lidocaine can alleviate the pain of propofol injection, but its application method and dose are controversial. It is worthy of further discussion on how to select the appropriate dose of advanced intravenous injection of lidocaine to effectively prevent the injection pain of mediate-long chain fat emulsion propofol, and simultaneously avoid the adverse reactions of intravenous lidocaine, thus improving patient satisfaction and perioperative safety. In this study, in order to provide clinical references, sequential method was used to find the median effective dose (ED50) by means of pre-intravenous injection of lidocaine to suppress pain in mediate-long chain fat emulsion propofol injection.


Eligibility Criteria:
Inclusion Criteria:

* Ages ranged from 18 to 65.
* ASA Ⅰ or Ⅱ level.

Exclusion Criteria:

* Allergy or contraindication to lidocaine or propofol; required for Central venipuncture catheterization;
* Abnormal liver or kidney function;
* Heavy drinking and long-term use of sedatives, analgesics or anti-anxiety drugs;
* Hearing and language impairment;
* Peripheral vascular disease;
* Severe cardiovascular disease or neurological disorders;
* Failure of one-time peripheral venipuncture;
* Infection of hand or wrist skin.
A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)

This is a Phase II, open-label, multicenter and multi-cohorts study of PLB1001 administered orally twice daily to locally advanced/metastatic NSCLC patients with c-Met dysregulation.

PLB1001 will be administrated 200mg twice daily. The treatment will be discontinued for the patients who experience disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent. A cycle of study treatment will be defined as 28 days of continuous dosing. The study includes 4 cohorts.

Eligibility Criteria:
Inclusion Criteria:

* Signed Informed Consent Form
* Age≥18 years
* Histologically or cytologically confirmed advanced non-small cell lung cancer
* Must have evidence of c-Met dysregulation from the results of molecular pre-screening evaluations
* At least one measurable lesion as per RECIST v1.1
* Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 1
* ECOG Performance Status of 0-1.

Exclusion Criteria:

* Symptomatic central nervous system (CNS) metastases that are neurologically unstable or requiring increasing doses of steroids to control, and patients with any CNS deficits.
* Clinically significant, uncontrolled heart diseases Unstable angina History of documented congestive heart failure (New York Heart Association functional classification \> II) Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) ≥ 160 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 100 mm Hg Arrhythmias
* Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1, except for alopecia
* Major surgery within 4 weeks prior to starting PLB1001
* Previous anti-cancer and investigational agents within 2 weeks before first dose of PLB1001. If previous treatment is a monoclonal antibody, then the treatment must be discontinued at least 4 weeks before first dose of PLB1001
* Pregnant or nursing women
* Involved in other clinical trials \< 2 weeks prior to Day. If previous treatment of clinical trial is a monoclonal antibody, then the treatment must be discontinued at least 4 weeks before first dose of PLB1001.
Impact of Tailored Preventive Exercise Program for Reducing Risk of Hip Adductors Injury

this study will be conducted :

* To investigate the impact of tailored preventive exercise program in reducing hip adductor loss of isometric strength in professional football players.
* To investigate the impact of tailored preventive exercise program in reducing hip adductors to abductors strength asymmetry ratio in professional football players.
* To investigate the impact of tailored preventive exercise program in reducing pain intensity during seasonal matches in professional football players.
* To investigate the impact of tailored preventive exercise program on groin health and performance enhancement in professional football players.

Football playing is associated with a high risk of injuries, which results in significant costs for the public health system and may even cause long-term disability for the injured player. The study's findings and the developed exercise program can have practical implications for athletic trainers, strength and conditioning coaches, and medical professionals working with professional football players. The program can serve as a valuable resource for designing individualized training regimens aimed at reducing adductor injury risk and optimizing performance in this specific sport population.

So, the study's significance lies in its focus on injury prevention programs, tailored training preventive programs, enhancing football players' performance on an evidence-based approach. Since there is still a lack of literature and a gap in this research area on the preventive exercise program related to sport injuries' field and as health care professionals, we must provide the best service for the players not only to increase their game performance but also to keep their long live journey of playing.

Eligibility Criteria:
Inclusion Criteria:

* Male football players only will be included in the study. Men's football had the second highest injury rates .
* Players will have loss in hip adductor strength more than 15% .
* Players will have hip adductor/abductor strength ratio in percent less than 80% or ratio less than 0.9.
* Participants will go under full documentation of groin health and injury history.
* Participants will Complain of muscle fatigue or spasm or mild pain on VAS will be 3 or less, during and after matches with no real injury.

Exclusion Criteria:

Presence of injuries at the level of the hip/hip region at the initial assessment

* Players with acute groin injuries.
* Players with recent hip and pelvic floor muscles problems.
* Players with acute hip adductor strains or tears.
* Players with inguinal hernia.
* Players who already don't play matches or stop training.
CPG 7909 in Patients With Cutaneous T-Cell Lymphoma

To assess the effect of CPG 7909 Injection on Cutaneous T-cell lymphoma and the safety of CPG 7909 Injection in patients with this cancer.


Eligibility Criteria:
Inclusion Criteria:

Patients 18 years or older with biopsy (histopathologically) confirmed cutaneous T-cell lymphoma (limited to mycosis fungoides (MF)) who have had prior therapy with at least one and no more than 3 systemic treatments.

Exclusion Criteria:

Patients with visceral involvement, serious infection or illness including human immunodeficiency virus infection, or a Karnofsky Performance Status (KPS) \< 60 will be excluded.
30 Day Rehospitalization Risk in Hemodialysis Patients

After a hospitalization, dialysis patients have a high risk of being admitted to the hospital again within 30 days. The purpose of this research study is to test a new way of reducing the chance of patients being hospitalized again. In this study investigator will evaluate a checklist driven evaluation upon return to the dialysis facility as a method to reduce the rate of rehospitalizations in hemodialysis patients.

There are an excessive number of 30 day readmissions after hospital discharges of dialysis patients in the U.S. (35.2%). Investigators recent research has found that approximately 2/3 of these readmissions are potentially avoidable. Investigators believe that among the causes for the excessive number of readmissions, the most important may be that patients usually do not receive a clinical assessment upon return to dialysis after a hospitalization. An all too common practice in the U.S. is for the nephrologist to not see the patient but to give verbal orders to the dialysis nurse to resume previous orders. This increases readmission risk in that there are a number of key clinical processes that if completed on return to dialysis might greatly reduce rehospitalization risk. Nephrologists are often not available to see patients in the peri-discharge period, but there is a trend towards an increasing number of U.S. dialysis facilities now having nurse practitioners (NP) working in the units. Investigators believe that NPs using a checklist can conduct a post-discharge clinical encounter that would allow for key care processes to be carried out and to direct telephone communication with the treating nephrologist. Our objective is to reduce the risk of dialysis patient readmissions within 30 days through the use of this intervention. Our research question is whether this intervention would be effective for reducing 30 day readmission risk. Our hypothesis is that the intervention will prove to be more effective then usual care for reducing 30 day readmission risk.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* Must have been an existing patients of the outpatient dialysis units for at least 1 month prior to the index hospitalization
* Index hospitalization must be from an acute care hospital

Exclusion Criteria:

* Hospital discharges against medical advice
* Assessment cannot be initiated within 96 hours of hospital discharge
* Primary hospital diagnosis related to cancer, renal transplant, mental health or rehabilitation
* Hospital admission was the 5th or more in the previous 12 months
* Failure to provide informed consent